Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program
<p>Advancing a First-in-Class Small-Molecule Therapeutic, Guided by World-Leading Experts, to Address a Multi-Billion-Dollar Unmet Need in Steroid-Refractory Patients REHOVOT, Israel, Oct. 28, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering computational chemistry...</p>
Read original article ↗
Related Articles
This is how badly X wants you to pay to promote your posts
After Elon Musk warned that "advertisers who post ads that are ugly, shrill, strident or overstate claims about their pr
Plato Raises $16 Million to Build the Training Grounds for AI's Next Leap Into Real Work
Plato gives AI developers a repeatable way to train and test models on the tools, decisions, and constraints that shape
NEW YORK, Oct. 28, 2026 /PRNewswire/ -- BetaNXT, a leading provider of wealth management technology solutions with real-
New ICIMS and Kyle & Co. Research Links AI Readiness and Deployment to Stronger Hiring Performance
ICIMS and Kyle & Co.'s 2026 Talent Transformation Yearbook surveys 500 HR and talent leaders and 1,000 U.S. job seekers,